NEW YORK, April 19 – In settling a suit with PerkinElmer Thursday, Genomic Solutions has paid PerkinElmer $5.5 million to buy back a large part of its stock, and given UK distribution rights to its products to PerkinElmer, but the settlement may make the company more attractive to investors, analysts are saying.

The settlement terminates PerkinElmer’s “call right” to shares of Genomic Solutions stock, which allowed PerkinElmer to call in all shares of Genomic Solutions and become the sole shareholder.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.